CASE REPORT article
Front. Med.
Sec. Nephrology
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1667519
Telitacicept administration improved immunoglobulin A nephropathy after hematopoietic stem cell transplantation: a case report
Provisionally accepted
- Department of Nephrology, First Hospital of Jilin University, Changchun, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Telitacicept is a biologic that specifically targets B-lymphocyte stimulator and a proliferation-inducing ligand, demonstrating significant potential for therapeutic applications in B-cell-mediated autoimmune diseases. Currently, telitacicept is primarily utilized in the treatment of systemic lupus erythematosus. However, its therapeutic effect on immunoglobulin A nephropathy (IgAN) after hematopoietic stem cell transplantation (HSCT) has not been reported. This case report presents the clinical outcome of telitacicept administration in the treatment of IgAN following HSCT. Case Report: A 36-year-old Asian man developed IgAN following allogeneic HSCT for acute myeloid leukemia (AML). The patient presented with features of high-risk nephrotic syndrome, including a urinary protein quantification of 8.28 g/24h and serum albumin level of 29 g/L. The patient showed significant clinical improvement following treatment with moderate-dose glucocorticoids combined with telitacicept. After the treatment process, the urine albumin quantification decreased to 0.23 g/24h, and serum albumin increased to 45.8 g/L. During the treatment, estimated glomerular filtration rate (eGFR) increased from 67.3 to 79.83 mL/min/1.73m2, and immune indicators immunoglobulin A (IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM) also demonstrated steady levels (IgA: 6.78-10.1 g/L, IgG: 0.5-1.41 g/L, IgM: 0.17-0.6 g/L). Notably, the patient's condition remained stable without any significant adverse effects throughout the rapid tapering of the glucocorticoid dose. Conclusion: This case suggests that telitacicept may be an effective treatment option for IgAN following HSCT, providing valuable insights into future therapeutic strategies for managing post-HSCT IgAN.
Keywords: IgA nephropathy, Telitacicept, Hematopoietic Stem Cell Transplantation, Glucocorticoids, Acute Myeloid Leukemia
Received: 16 Jul 2025; Accepted: 28 Aug 2025.
Copyright: © 2025 Yuan, Dan, Zhang and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dong Dan, Department of Nephrology, First Hospital of Jilin University, Changchun, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.